Brain mapping instruments Market is anticipated to grow at a considerable CAGR of 6.1% during the forecast period (2024-2031). The global brain mapping instruments market is fueled by advancements in neuroscience research, the increasing prevalence of neurological disorders, technological innovations, government, and private funding, clinical applications, increasing awareness and education, globalization, partnerships, and regulatory landscape. Advancements in neuroscience research, the need for sophisticated tools to capture detailed data, and the increasing prevalence of neurological disorders like Alzheimer's, Parkinson's, epilepsy, and stroke drive the demand for brain mapping instruments. Government and private funding initiatives, as well as increased awareness about brain health and early detection, contribute to market growth. Collaborations between industry players, academic institutions, and research organizations foster innovation in brain mapping instruments.

Market Dynamics

Increased Diagnosis And Monitoring Needs

Global health is at risk from neurological disorders, that call for precise diagnosis and ongoing observation. Tools for brain mapping are essential for the advancement of disease and the effectiveness of treatment. According to the World Health Organization (WHO), in March 2024, there was a significant global prevalence of neurological conditions, affecting over 3.0 billion individuals. Neurological conditions have emerged as the primary cause of ill health and disability globally. The overall burden of disability, illness, and premature death caused by these conditions has witnessed an 18.0% increase. Notably, access to treatment for neurological conditions varies greatly, with high-income countries having substantially more neurological professionals per 100,000 individuals compared to low- and middle-income countries, where over 80.0% of neurological deaths and health loss occur. 

Increased Funding For Brain Mapping Research

Brain Connects offers significant funding for brain mapping research, promoting the development of novel technologies and propelling market expansion via partnerships, technology transfer, and research product commercialization. For instance, National Institute of Neurological Disorders and Stroke (.gov), in September 2023, the NIH BRAIN Initiative launched projects to develop innovative technologies to map the brain in detail. The initiative aims to uncover the logic of the brain's neural code, helping to understand how it makes us who we are and how it could be re-wired to treat brain diseases. The initial round of BRAIN CONNECTS awards supports 11 grants, totaling $150.0 million over five years. The projects will use cutting-edge technology to image and analyze brain connectivity, develop pipelines for data collection and analysis, and develop complementary brain mapping technologies.

Market Segmentation

Our in-depth analysis of the global brain mapping instruments market includes the following segments by product, and end-user:

• Based on the product, the market is sub-segmented into computed axial tomography (CAT), positron emission tomography, electroencephalography (EEG), functional near-infrared spectroscopy (fNIRS), functional magnetic resonance imaging (fMRI), and other (magnetoencephalography (MEG) systems, and transcranial magnetic stimulation (TMS) devices).

• Based on end-users, the market is sub-segmented into hospitals and clinics, diagnostic centers, and others (research institutes and academic centers).

Computed Axial Tomography (CAT) is Projected to Emerge as the Largest Segment

Based on the disease indication, the global brain mapping instruments market is sub-segmented into computed axial tomography (CAT), positron emission tomography, electroencephalography (EEG), functional near-infrared spectroscopy (fNIRS), functional magnetic resonance imaging (fMRI), and others. Among these, the computed axial tomography (CAT) sub-segment is expected to hold the largest share of the market. The primary factor supporting the segment's growth includes the use of neuroimaging, such as MRIs and CT scans, which is growing in the diagnosis and monitoring of neurological diseases. This rise has been prompted by the need for sophisticated brain mapping tools. According to the Diagnostic Imaging Dataset Statistical, in May 2023, the total number of imaging tests reported in England from February 2022 to January 2023 was 43.4 million. In January 2023, the most commonly performed tests were Plain Radiography (X-ray) with 1.7 million, followed by Diagnostic Ultrasonography (Ultrasound) with 0.8 million, Computerized Axial Tomography (CT Scan) with 0.5 million, and Magnetic Resonance Imaging (MRI) with 0.3 million.

Hospitals and Clinics Sub-segment to Hold a Considerable Market Share

To enhance the clinical need and demand for precision medicine in neurosurgery and improve patient outcomes during tumor removal, a brain mapping gadget is being introduced. This technology allows surgeons to navigate essential brain locations with accuracy. For instance, in August 2022, Delhi Hospital launched a unique "brain mapping device," claiming it is the first of its kind in the country. The device combines research and advanced technology to improve treatment for brain tumors and avoid damage to critical brain areas. 

Regional Outlook

The global brain mapping instruments market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America). 

Government for Healthcare Innovation In Asia-Pacific Region

The government's focus on healthcare infrastructure and increased funding fosters innovation in the sector, including support for brain mapping instrument manufacturers to improve product accuracy, efficiency, and affordability. According to Healthcareradius, in February 2024, the total healthcare expenditure showed an increase from $9.6 billion in 2023-24 to $10.9 billion in 2024-25. Additionally, there has been a significant increase in the allocation for the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PMABHIM), which has risen from $25.4 billion in 2023-24 to $49.7 billion in 2024-25.

Global Brain Mapping Instruments Market Growth by Region 2024-2031

North America Holds Major Market Share

The increasing dementia prevalence prompts investments in advanced neuroimaging technologies, focusing on brain mapping instruments with higher sensitivity, resolution, and specificity for early dementia detection and disease progression monitoring. According to the World Health Organization, in March 2023, Dementia affects a significant number of individuals globally, with over 55.0 million individuals currently living with the condition. The majority of these individuals (over 60.0%) reside in low- and middle-income countries. Each year, there are nearly 10.0 million new cases reported. Alzheimer's disease, the most common form of dementia, accounts for 60-70.0% of these cases. Dementia is a leading cause of death and contributes to disability and dependency among older individuals globally. In 2019, the economic cost of dementia was estimated at $1.3 trillion, with approximately 50.0% of these expenses attributed to informal carers, that provide an average of 5 hours of care and supervision per day. Women are disproportionately affected by dementia, both in terms of higher disability-adjusted life years and mortality rates, in addition to being responsible for 70.0% of the caregiving hours for individuals with dementia.

Market Players Outlook

*Note: Major Players Sorted in No Particular Order.

The major companies serving the global brain mapping instruments market include General Electric Co., Koninklijke Philips N.V., Medtronic PLC, Canon Medical Systems Corp., and Siemens Healthineers co., among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers, and acquisitions to stay competitive in the market. For instance, in May 2023, Lenox Hill Hospital, adopted Quicktome, a brain-mapping neurotechnology, to improve neurosurgery efficiency. The FDA-cleared platform uses MRI scans to automatically map a patient's unique brain network before surgery.

The Report Covers

• Market value data analysis of 2023 and forecast to 2031.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global brain mapping instruments market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.